Ranolazine, sold under the trade name Ranexa by Gilead Sciences (who acquired the developer, CV Therapeutics in 2009), is an antianginal medication. In India, it is sold under the name "Ranozex". On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina pectoris.

Read more about RanolazineMechanism of Action, Indications For Use, Contraindications, Metabolism

Other articles related to "ranolazine":

Ranolazine - Approval - United States
... has approved a new, first-line indication for ranolazine for the treatment of chronic angina ... The new labeling also provides information showing ranolazine reduced arrhythmias, including ventricular arrhythmias, new onset atrial fibrillation and a potentially dangerous slow heartbeat known as ... According to the revised labeling, ranolazine is indicated for the treatment of chronic angina and may be used alone or in combination with traditional therapies for chronic angina ...